Targeted nanoplatform reduces microglial senescence and eases motor deficits in Parkinson mice
Silencing the upregulated gene PLXDC2 via brain-penetrating nanoparticles suppressed cGAS-STING signaling, reduced iron accumulation, and protected dopaminergic neurons.
Advanced science (Weinheim, Baden-Wurttemberg, Germany) · Lu H et al. · Paper published 27 Sep 2026
In human substantia nigra single-cell data and mouse models of Parkinson's disease, researchers investigated how targeting the PLXDC2 gene affects disease progression. By analyzing the human tissue atlas, the team identified elevated PLXDC2 expression in microglia. They then engineered a biomimetic nanoplatform coated with a ferritin-modified microglial membrane to deliver PLXDC2-silencing siRNA alongside the iron chelator deferoxamine and antioxidant cerium oxide nanoparticles. In mice with Parkinson's disease, the nanoplatform successfully crossed the blood-brain barrier. The intervention decreased iron deposition, diminished reactive oxygen species, and curbed neuroinflammation. Silencing PLXDC2 mitigated microglial senescence driven by the cGAS-STING signaling pathway. Consequently, the treated mice experienced reduced dopaminergic neurodegeneration and showed measurable improvements in motor performance, including balance, coordination, and endurance.
Why it matters
Microglial senescence and chronic neuroinflammation are prominent hallmarks of age-related neurodegenerative disorders. Linking PLXDC2 to cGAS-STING-mediated senescence offers a defined molecular target to address both cellular aging and pathological microenvironments in the brain.
Caveats
The therapeutic outcomes were demonstrated exclusively in mouse models, which may not fully capture human pathology. Additionally, the abstract does not report long-term safety, off-target effects, or translational pharmacokinetics for this multi-component delivery platform.
Written from the paper’s abstract, and every claim checked against it before publishing. Read the paper for the full methods and data.
The paper
PLXDC2 siRNA-Mediated Intervention Attenuates Microglial Senescence Through cGAS-STING Signaling
Lu H, Zheng Z, Wang F et al.
Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 27 Sep 2026 · Peer-reviewed
- Relevance
- Relevant
- News value
- Notable
- Evidence
- Animals
- Status
- Peer-reviewed
More on Cellular senescence
See allDasatinib and quercetin reduce liver fibrosis in a phase-2 MASH trial
The senolytic combination improved liver fibrosis without disease worsening in nearly half of treated participants while lowering cellular senescence markers.
Nature metabolism · Koning M et al.
A distinct p21-driven macrophage senotype accumulates during aging and liver disease
Researchers identified a p53-p21-Cyclin D2 axis that governs senescent macrophages in mice and human liver cirrhosis and can be cleared with senolytics.
bioRxiv · Torres G et al.
DNA methylation proxies of senescence markers track human disease and mortality
The new blood-based tools estimate senescence gene activity to predict incident diseases, all-cause mortality, and clinical treatment responses.
medRxiv · Simpson DJ et al.
Bispecific T cell engager eliminates senescent cells in mice and nonhuman primates
Monitored by serum transaminase levels, low doses of the drug alleviated age-related pathologies without causing the hepatotoxicity seen at higher doses.
Aging cell · Deng J et al.
A deep learning score for cellular senescence predicts human mortality and disease risk
The proteomic biomarker tracked chronic illness risk in the UK Biobank and shifted following an 18-month multimodal exercise intervention.
Aging cell · Zhao S et al.